| Item type |
学術雑誌論文 / Journal Article(1) |
| 公開日 |
2021-09-01 |
| タイトル |
|
|
タイトル |
Assessment of Immune-Related Interstitial Lung Disease in Non-Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors: A Multi-Center Prospective Study |
|
言語 |
en |
| 言語 |
|
|
言語 |
eng |
| キーワード |
|
|
主題 |
Immune checkpoint inhibitor |
| キーワード |
|
|
主題 |
Programmed death 1 (PD-1) |
| キーワード |
|
|
主題 |
Non-small cell lung cancer (NSCLC) |
| キーワード |
|
|
主題 |
immune-related interstitial lung disease |
| キーワード |
|
|
主題 |
spirometry |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
journal article |
| その他のタイトル |
|
|
その他のタイトル |
Impaired spirometry predicts ir-ILD |
| 著者 |
Suzuki, Yuzo
Karayama, Masato
Uto, Tomohiro
Fujii, Masato
Matsui, Takashi
Asada, Kazuhiro
Kusagaya, Hideki
Kato, Masato
Matsuda, Hiroyuki
Matsuura, Shun
Toyoshima, Mikio
Mori, Kazutaka
Ito, Yasuhiro
Koyauchi, Takafumi
Yasui, Hideki
Hozumi, Hironao
Furuhashi, Kazuki
Enomoto, Noriyuki
Fujisawa, Tomoyuki
Nakamura, Yutaro
Inui, Naoki
Suda, Takafumi
|
| 書誌情報 |
Journal of thoracic oncology
巻 15,
号 8,
p. 1317-1327,
発行日 2020-08
|
| 出版者 |
|
|
出版者 |
Elsevier |
| 権利 |
|
|
権利情報 |
Copyright 2020 Elsevier. This manuscript version is made available under the CC-BY-NC-ND 4.0 license https://creativecommons.org/licenses/by-nc-nd/4.0/ |
| 権利 |
|
|
権利情報 |
"This is the accepted manuscript version. The formal published version is available at ""https://doi.org/10.1016/j.jtho.2020.04.002""." |
| 抄録 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
Introduction: Programmed death-1 immune checkpoint inhibitors (ICIs) have been shown to improve survival of non-small cell lung cancer (NSCLC) patients. Upon expansion of clinical administration for a variety of cancers, immure-related adverse events (ir-AEs) have been typically recognized to be associated with ICIs therefore, necessitating the monitoring and management of these patients. Among ir-AEs, immune-related interstitial lung disease (ir-ILD) is a serious complication which interrupts treatment and occasionally, is fatal. However, no prospective studies have investigated incidences of ir-ILD and associated risk factors for its development in the clinical setting.
Methods: This was a prospective cohort study consisting of NSCLC patients treated with ICIs. Baseline characteristics, including laboratory data, pulmonary function tests (PFTs), daily dyspnea defined by the modified Medical Research Council (mMRC), and anti-tumor response were assessed.
Results: Among the 138 NSCLC patients that received anti-PD-1 monotherapy, 20 patients (14.5%) developed ir-ILD within median 51.5 days [29-147: interquartile]. This was approximately three-times higher than those in clinical trials. Eleven patients (55.0%), including all of eight patients with high-grade ir-ILD (?Grade 3), developed ir-ILD within 60 days. Impaired spirometry, decreased forced vital capacity (%FVC) and forced expiratory volume in 1.0 second (%FEV1), and daily dyspnea measured by mMRC were identified as risk factors for ir-ILD development. Additionally, combination assessment of %FVC and %FEV1 successfully classified patients at risk for ir-ILD development.
Conclusion: The incidences of ir-ILD were substantially higher in clinical setting. Assessment of spirometry and daily dyspnea before ICI treatment may be useful to monitor and manage NSCLC patients. |
| ISSN |
|
|
収録物識別子タイプ |
ISSN |
|
収録物識別子 |
1556-0864 |
| EISSN |
|
|
収録物識別子タイプ |
ISSN |
|
収録物識別子 |
1556-1380 |
| PubMed番号 |
|
|
関連タイプ |
isVersionOf |
|
|
識別子タイプ |
PMID |
|
|
関連識別子 |
32289515 |
| 出版社DOI |
|
|
関連タイプ |
isVersionOf |
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
10.1016/j.jtho.2020.04.002 |
| 著者版フラグ |
|
|
出版タイプ |
AM |
|
出版タイプResource |
http://purl.org/coar/version/c_ab4af688f83e57aa |
JTO-15-1317.pdf (1.8 MB)
.png)
